Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. - Wikidata - awgldk - TriplyDB

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

http://www.wikidata.org/entity/Q35012871

about

Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung Current status of mucins in the diagnosis and therapy of cancer.ProtEx technology for the generation of novel therapeutic cancer vaccines MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer.EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.Recent advances in the development of breast cancer vaccines.Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Dendritic cell immunotherapy: clinical outcomes Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.MUC1-Targeted Cancer Cell Photothermal Ablation Using Bioinspired Gold Nanorods.Presentation Modality of Glycoconjugates Modulates Dendritic Cell Phenotype.Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1 Natural and Induced Humoral Responses to MUC1.Strategies used for MUC1 immunotherapy: human clinical studies.Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors.Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.Progress in the development of a therapeutic vaccine for breast cancer.MUC1 and metastatic cancer: expression, function and therapeutic targeting.MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.MUC1 immunotherapy.MUC1 immunotherapy is here to stay.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.C-type Lectin Receptors for Tumor Eradication: Future Directions.Emerging immunotherapy strategies in breast cancer.Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen.A Review of Water-Resistant Hemicellulose-Based Materials: Processing and Applications.Multiple Sclerosis: Immunopathology and Treatment Update.Cancer immunotherapy.Mannan-mediated gene delivery for cancer immunotherapy.MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1.Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.Progress in Vaccine Therapies for Breast Cancer.Mannosylated T/Tn with Freund's adjuvant induces cellular immunity.

P2860

Q30373884-2FC125BC-10B5-4730-8665-F37A687984E5 Q33757326-8A956E10-03F4-4E9D-A216-BB2B9D434277 Q34048819-6040CDA2-C913-49CA-A35F-6E909CA02196 Q34206162-52413E36-2DD5-411A-A194-31CC5B71252C Q34269196-6E602A71-384D-42B8-AC0D-67CE60632927 Q34379303-C1380E95-7DD3-445F-AEE0-F4E7BEE7B246 Q34494018-157D42A1-67EE-40AF-AD53-C8A3A4089A5B Q34511606-38CDADF9-4BD9-4CD5-B972-9BE890E9D840 Q35551987-06B3D693-B6A4-4A39-9C4D-0012CF74AAFB Q35683902-CBAFE15C-0355-4B17-A0A4-2E15D15BBA71 Q35801322-38006F5A-2A41-4804-A177-C5F2235B97BE Q36510283-232E5661-5C80-4D18-BEC0-16CE5E21EACD Q36915898-03059878-1535-4ACA-975C-DA69949FE251 Q37137385-68184A53-4AF1-4944-A204-C1809E31DB4D Q37259597-2576704F-DC12-4E12-A4B8-999972B6F3CA Q37259611-ECABC3E2-ED8B-4B1E-8AE4-6CE5255453AE Q37338140-CF1877A2-2F89-4221-AE55-0DBC6A84B185 Q37354177-73617B59-8652-4265-8AD5-E27BD2876A47 Q37355578-D56D0934-8680-498B-B49C-A802384ECDDE Q37636939-96C762A6-A5D3-4818-B5B5-D7F19B9FA631 Q37737313-44702E5E-9FD6-408A-AC21-82E37326E7EA Q37773241-1D893A4E-127D-406F-A8CA-0661BE4D4ABC Q38045428-B3FA0EA1-D65A-46E6-A78C-9B9EEAC390B6 Q38091088-969CA31C-BD54-4EA8-AC11-37A02CE8E83E Q38161368-4D5B53A3-D9E6-4F94-820F-D5707C9E0220 Q38184650-A4C6CD53-EFCB-4C2C-BA4E-090B64CC2D4B Q38336731-12B53894-707D-4BDD-8B32-92CB2712F076 Q38603410-1C6DE75F-50FC-4EA1-AED6-8C7113784AB7 Q38966611-2D7C14D1-24EC-4407-8262-83E3E021BD3C Q39060582-4DD0E4CD-DB81-4CF1-8892-764ECB9D8CC3 Q39420793-8A0D4A6F-78E2-45DC-B381-78DFC0A2B2D6 Q39958332-3A2CD368-DDE0-49F5-9780-24A40A10978D Q40165469-8FD7940F-5B93-447F-9FDA-7B62D78E9308 Q40197046-284E0CDA-EA16-4E8D-83F8-8BFA3C971166 Q41201112-CF6B7CDB-609C-4BFA-9B87-A73044D6C56B Q42160992-ECB8537F-5607-482F-9440-192CE15DE4F9 Q46437199-9729AF16-0D61-49AF-85BD-9FA294535063 Q47233994-4007AB5E-FD12-44B0-891F-64062E44106C Q48556381-0D3F2C14-EE46-41BA-B792-DF001BFACC6F Q48566108-DC7C1EED-E5C6-4BC3-9277-BF44F151BAF2

P2860

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

http://www.wikidata.org/entity/Q35012871

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@ast

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@en

type

label

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@ast

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@en

prefLabel

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@ast

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@en

P1433

Q35012871-0290125C-53DF-4EFF-A722-CAF6CD64B552

P1476

Q35012871-DC3EBABD-EF0C-4D09-96CA-CB7097ACDBD7

P2093

Q35012871-23874045-9185-4D23-845F-6E4AE3EA7261

Q35012871-4FDE6E38-0402-4D3F-9B35-0573E0023944

Q35012871-60B92CB0-CAF0-4558-816D-D43995C38511

Q35012871-6816DA8B-CF85-4842-B435-591BF1498B4C

Q35012871-908449CD-766C-4719-A680-D4D275CA4EF7

Q35012871-A5B82281-8311-458A-BB26-42E2629CA93C

Q35012871-AEC26520-3AB8-4D5C-9C95-03F455D14796

Q35012871-B987438D-F608-40D2-AEC3-2A26990E5860

Q35012871-BE53D06B-7E4C-43BB-BCFD-9E8D5BBA02F9

Q35012871-D8A941C4-2B35-487B-8646-27818152F21E

P2860

Q35012871-02FB4A6F-E01B-4EBE-978C-CF36212C21A7

Q35012871-03D6D74D-8373-4118-B56A-2A21C238A200

Q35012871-0D68AA3C-83CB-483C-B28B-ECB436AF4655

Q35012871-15D1B39C-3B82-46F3-A935-5AB8315825AA

Q35012871-18AD4A7F-A252-4AED-A7A3-98942F5A320D

Q35012871-2453549E-D589-45C1-9CF4-403481A32F12

Q35012871-2A046D07-C8C5-425A-9C20-1BCB8C33600E

Q35012871-31174AB8-5651-4C5B-B52C-7B8DD2FEA097

Q35012871-4588EE7E-2ED9-4171-A040-7F52FF82A479

Q35012871-4744A8C4-BF49-4F99-9314-E98DF767BEDF

P2888

Q35012871-3EC72C0A-46B7-412E-B830-79A44E66E3E6

P304

Q35012871-754B2198-3431-4B99-A33D-0938EE8A5F42

P31

Q35012871-502772F8-9814-4018-A786-E1B9956E6BCE

P356

Q35012871-5AF2600D-3BC0-4486-B8BA-894EF7958530

P433

Q35012871-B82A9EB2-D5C7-4866-93EF-E9201EAACC10

P478

Q35012871-450C0406-E25C-4BC0-84DF-CF8684E76E57

P50

Q35012871-232E42DD-B717-42E6-A863-1D7AEA1EF925

P577

Q35012871-35F46F29-9922-4536-A236-076BB8A2E0F9

P5875

Q35012871-A77886BA-FE04-4721-939A-05F1F3EFB901

P6179

Q35012871-5EF479D0-D303-40C9-A680-A21574C2776D

P698

Q35012871-571734DC-1AA0-4EA9-A77B-13416EF549A9

P921

Q35012871-3820FC85-74AC-47EC-8A91-10CF03EA7225

P932

Q35012871-E1EB0386-A799-49C6-BC42-FDC4F94FCE57

P356

P1433

Breast Cancer Research

P1476

Pilot phase III immunotherapy ...... mannan-MUC1 [ISRCTN71711835].

@en

P2093

Anastasios Tsibanis

http://www.w3.org/2001/XMLSchema#string

Annivas Tsikkinis

http://www.w3.org/2001/XMLSchema#string

Bruce E Loveland

http://www.w3.org/2001/XMLSchema#string

Dodie S Pouniotis

http://www.w3.org/2001/XMLSchema#string

Geoffrey A Pietersz

http://www.w3.org/2001/XMLSchema#string

Heleni Drakaki

http://www.w3.org/2001/XMLSchema#string

Ian F McKenzie

http://www.w3.org/2001/XMLSchema#string

Magdalena Plebanski

http://www.w3.org/2001/XMLSchema#string

Michael N Alexis

http://www.w3.org/2001/XMLSchema#string

Sara J Piddlesden

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Generation of cellular immune responses to antigenic tumor peptides.

Generation of MUC1 cytotoxic T-cells in mice and epitope mapping.

Role of the mannose receptor in the immune response.

MUC1 and breast cancer.

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein.

P2888

P304

R27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR1505

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Vasso Apostolopoulos

P577

2006-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7006557

http://www.w3.org/2001/XMLSchema#string

P6179

1002067821

http://www.w3.org/2001/XMLSchema#string

P698

16776849

http://www.w3.org/2001/XMLSchema#string

P921

P932

1557739

http://www.w3.org/2001/XMLSchema#string